李永明（邮箱：liyongming1979@sina.com），理学博士，教授，硕士研究生导师。先后在美国北达科他州立大学、密歇根大学和乔治华盛顿大学担任博士后和研究助理教授， 2018年到南京中医药大学工作，入选江苏省“六大人才高峰”高层次人才培养对象。中国细胞生物学学会会员，中国中西医结合学会会员。

主要从事肿瘤细胞生物学以及肝肠疾病的发病机制和干预策略研究，先后主持国家级与省部级自然科学基金课题4项，相关研究成果发表SCI论文30余篇，申请专利2项。担任J Biol Chem、Cancer Medicine、International Journal of Oncology 等学术杂志审稿人。

代表性研究论文

[1]Tong Wang, Mengmeng Zhang, Muhammad Khan*, Jingjing Li, XiaoWu, Tonghui Ma*, Yongming Li*. “Cryptotanshinone suppresses ovarian cancer via simultaneous inhibition of glycolysis and oxidative phosphorylation”.  Biomedicine & Pharmacotherapy, 170 (2024) 115956, https://doi.org/10.1016/j.biopha.2023.115956 

[2]Haijian Sun , Yunke Guo, Haidan Wang, Ailing Yin, Jing Hu, Tianjie Yuan, Shuxin Zhou, Weichen Xu, Peng Wei, Shusheng Yin, Panru Liu, Xi Guo,Yizhao Tang, Yujiao Yan, Zichen Luo, Majie Wang, Qingqing Liang, Peng Wu, Aifeng Zhang, Zhuxiu Zhou, Yueyue Chen, Yongming Li*, Jing Li* , Jinjun Shan*,Wei Zhou*. “Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis”. Gut, 2023;0:1–14. doi:10.1136/gutjnl-2022-327756

[3]Tong Wang, Shusheng Yin, Juan Gu, Jingjing Li, Mengmeng Zhang, Jinjun Shan, Xiao Wu,* and Yongming Li*. Study on the Intervention Mechanism of Cryptotanshinone on Human A2780 Ovarian Cancer Cell Line Using GC-MS-Based Cellular Metabolomics. Pharmaceuticals, 2023,16, 861. https://doi.org/10.3390/ph16060861.

[4]Chi-Wei Chen＃, Yongming Li＃, Shuya Hu, Wei Zhou1, Yunxiao Meng1, Zongzhu Li1, Yi Zhang, Jing Sun, Zhou Bo, Melvin L. DePamphilis, Yun Yen, Zhiyong Han, Wenge Zhu. “ DHS (trans−4,4′-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2) ”. Oncogene, 2019, 38(13):2364-2379 . 

[5]Yongming Li＃, Zongzhu Li＃, Ruiqin Wu, Zhiyong Han and Wenge Zhu. “And-1 is required for homologous recombination repair by regulating DNA end resection”. Nucleic Acids Research, 2017, 45(5): 2531–2545.